The response-to-retention hypothesis of atherogenesis reinforced

Current Opinion in Lipidology

Volumn 9, Issue 5, 1998, Pages 471-474

  Williams, Kevin Jon ^a   Tabas, Ira ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Departments of Pathology and Cell Biology and Pharmacology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PROTEOGLYCAN;

ARTERY WALL; ATHEROGENESIS; GENETIC ENGINEERING; HUMAN; HYPERLIPIDEMIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; SITE DIRECTED MUTAGENESIS; VASCULAR ENDOTHELIUM;

ANIMALS; APOLIPOPROTEINS B; ARTERIOSCLEROSIS; HUMANS; LIPOPROTEINS; MICE; MODELS, BIOLOGICAL;

MURINAE;

EID: 0031761005     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199810000-00012     Document Type: Short Survey

References (40)

1. Anischkow N, Chalatow S. Über experimentelle cholesterinsteatose und ihre bedeutung für die entstehung einiger pathologischer prozesse. Zentralbl Allg Pathol 1913; 24:1-9.
2. Kannel WB, Wilson PW. Efficacy of lipid profiles in prediction of coronary disease. Am Heart J 1992; 124:768-774.
3. 100 severely affects proteoglycan interaction without affecting LDL receptor binding. J Clin Invest 1998; 101:2658-2664.
4. Borén J, Olin K, O'Brien KD, Arnold KS, Ludwig EH, Wight TN, et al. Engineering non-atherogenic low density lipoproteins: direct evidence for the 'Response-to-Retention' hypothesis of atherosclerosis [abstract]. Circulation 1998; in press.
5. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15:551-561.
6. Smith EB. The relationship between plasma and tissue lipids in human atherosclerosis. Adv Lipid Res 1974; 12:1-49.
7. Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis 1989; 9:908-918.
8. Hurt-Camejo E, Olsson U, Wiklund O, Bondjers G, Camejo G. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Arterioscler Thromb Vasc Biol 1997; 17:1011-1017.
9. Williams KJ, Fuki IV. Cell-surface heparan sulfate proteoglycans: dynamic molecules mediating ligand catabolism. Curr Opin Lipidol 1997; 8:252-261
10. Ji ZS, Fazio S, Mahley RW. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J Biol Chem 1994; 269:13421-13428.
11. Mann WA, Meyer N, Weber W, Meyer S, Greten H, Beisiegel U. Apolipoprotein E isotorms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia. J Lipid Res 1995; 36:517-525.
12. Purcell-Huynh DA, Farese RV Jr, Johnson DF, Flynn LM, Pierotti V, Newland DL, et al. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest 1995; 95:2246-2257.
13. 48 are both atherogenic.
14. Goldberg IJ, Paka L, Pang L, Obunike JC, Pillarisetti S. Evidence that the amino-terminal region of apolipoprotein B is the atherogenic portion of low density lipoprotein [abstract]. Circulation 1997; 96 (Suppl. 1):39.
15. Goldstein JL, Brown MS. Atherosclerosis: the low-density lipoprotein receptor hypothesis. Metabolism 1977; 26:1257-1275.
16. Schissel SL, Jiang X-C, Tweedie-Hardman J, Jeong TS, Camejo EH, Najib J, et al. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH: implications for atherosclerotic lesion development. J Biol Chem 1998; 273:2738-2746.
17. Schissel SL, Keesler GA, Schuchman EH, Williams KJ, Tabas I. The cellular trafficking and zinc-dependency of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene. J Biol Chem 1998; 273:18250-18259.
18. •] describe the enzymology and regulation of secretory sphingomyelinase, a candidate to explain aggregation of atherogenic lipoproteins retained in the arterial wall. Surprisingly, both this enzyme and the lysosomal sphingomyelinase are products of the same gene, and both appear to be zinc metalloenzymes, yet they can be regulated independently.
19. Mourao PA, Pillai S, Di Ferrante N. The binding of chondroitin 6-sulfate to plasma low density lipoprotein. Biochim Biophys Acta 1981; 674:178-187.
20. Srinivisan SR, Xu JH, Vijayagopal P, Radhakrishnamurthy B, Berenson GS. Low-density lipoprotein binding affinity of arterial chondroitin sulfate proteoglycan variants modulates cholesteryl ester accumulation in macrophages. Biochim Biophys Acta 1995; 1272:61-67.
21. •].
22. •]. report human homologs to the chick chondroitin 6-sulfotransferase, the key enzyme in the synthesis of chondroitin 6-sulfate, a glycosaminoglycan known to bind avidly to LDL. These studies are part of an important trend, namely the application of molecular methods to glycosaminoglycan assembly.
23. Klezovitch ON, Edelstein C, Scanu AM. Apolipoprotein (a) binds to proteoglycan decorin via its C-terminal domain [abstract]. Circulation 1997; 96 (Suppl. 1):112.
24. Pillarisetti S, Paka L, Obunike JC, Berglund L, Goldberg IJ. Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. J Clin Invest 1997; 100:867-874.
25. Nielsen LB, Juul K, Nordestgaard BG. Increased degradation of lipoprotein (a) in atherosclerotic compared with nonlesioned aortic intima-inner media of rabbits: in vivo evidence that lipoprotein (a) may contribute to foam cell formation. Arterioscler Thromb Vasc Biol 1998; 18:641-649.
26. 2 in the arterial wall and its relation to atherosclerosis. This enzyme generates lysophosphatidlycholine, a biologically active lipid, and this study shows assocation of this enzyme with retained lipid in atherosclerotic lesions.
27. Ivandic B, deBeer FC, deBeer MC, Castellani L, Leitinger N, Hama SY, et al. Transgenic mice overexpressing secretory phospholipase A2 develop markedly increased aortic fatty streak lesions [abstract]. Circulation 1996; 94 (Suppl. 1):152.
28. Zhu Y, Lin JHC, Liao HL, Friedli O, Verna L, Marten NW, et al. LDL induces transcription factor activator protein-1 in human endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18:473-480.
29. Allen S, Khan S, Al-Mohanna F, Batten P, Yacoub M. Native low density lipoprotein-induced calcium transients trigger VCAM-1 and E-selectin expression in cultured human vascular endothelial cells. J Clin Invest 1998; 101:1064-1075.
30. Tulenko TN, Chen M, Mason PE, Mason RP. Physical effects of cholesterol on arterial smooth muscle membranes: evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis. J Lipid Res 1998; 39:947-956.
31. Napoli C, D'Armiento FP, Mancini FP, Postiglione A, Witztum JL, Palumbo G, Palinski W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimai accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997; 100:2680-2690. A remarkable study on early arterial lesions during human fetal development. Retention and modification of atherogenic lipoproteins in the arterial wall occur first, followed by cellular infiltration, supporting the model that lipoprotein retention is the key initiating event even in the human disease.
32. Sakai A, Kume N, Nishi E, Tanoue K, Miyasaka M, Kita T. P-selectin and vascular cell adhesion molecule-1 are locally expressed in aortas of hypercholesterolemic rabbits before intimai accumulation of macrophages and T lymphocytes. Arterioscler Thromb Vasc Biol 1997; 17:310-316.
33. Fruebis J, Bird DA, Pattison J, Palinski W. Extent of antioxidant protection of plasma LDL is not a predictor of the antiatherogenic effect of antioxidants. J Lipid Res 1997; 38:2455-2464.
34. Zhang SH. Reddick RL, Avdievich E, Surles LK, Jones RG, Reynolds JB. et al. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J Clin Invest 1997; 99:2858-2866.
35. Bird DA, Tangirala RK, Fruebis J, Steinberg D, Witztum JL, Palinski W. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice. J Lipid Res 1998; 39:1079-1090.
36. Gugliucci Creriche A, Stahl AJ. Glycation and oxidation of human low density lipoproteins reduces heparin binding and modifies charge. Scand J Clin Lab Invest 1993; 53:125-132.
37. Öörni K, Pentikäinen MO, Annila A, Kovanen PT. Oxidation of low density lipoprotein particles decreases their ability to bind to human aortic proteoglycans. Dependence on oxidative modification of the lysine residues. J Biol Chem 1997; 272:21303-21311.
38. Kaplan M, Aviram M. Oxidized LDL binding to a macrophage-secreted extracellular matrix. Biochem Biophys Res Commun 1997; 237:271-276.
39. Kaplan M, Williams KJ, Mandel H, Aviram M. Role of macrophage glycosaminoglycans in the cellular catabolism of oxidized LDL by macrophages. Arterioscler Thromb Vasc Biol 1998; 18:542-553.
40. Halvorsen B, Aas UK, Kulseth MA, Drevon CA, Christiansen EN, Kolset SO. Proteoglycans in macrophages: characterization and possible role in the cellular uptake of lipoproteins. Biochem 1998; 331:743-752.